Literature DB >> 1489206

In vitro activity of Ro 23-9424 against clinical isolates of Legionella species.

P H Edelstein1, M A Edelstein.   

Abstract

Agar and broth microdilution MICs of Ro 23-9424 that inhibited 90% of 22 Legionella clinical isolates tested were 0.64 and 0.08 micrograms/ml, respectively; respective erythromycin values were 1.0 and 0.12 micrograms/ml. Ro 23-9424 (1 microgram/ml) was slightly more active than the same erythromycin concentration in a macrophage system, for both Legionella pneumophila strains studied.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1489206      PMCID： PMC284376          DOI： 10.1128/AAC.36.11.2559

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Weidenfeld; M B Dorr
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.

Authors:  J W Gu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

3.  In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.

Authors:  G Beskid; V Fallat; E R Lipschitz; D H McGarry; R Cleeland; K Chan; D D Keith; J Unowsky
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  Antimicrobial activity of imipenem and SCH34343 against Legionella species.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1987-04       Impact factor: 2.803

5.  Antibiotic susceptibility of Legionella pneumophia Philadelphia-1 in cultured guinea-pig peritoneal macrophages.

Authors:  S Yoshida; Y Mizuguchi
Journal:  J Gen Microbiol       Date:  1984-04

6.  Mode of action of the dual-action cephalosporin Ro 23-9424.

Authors:  N H Georgopapadakou; A Bertasso; K K Chan; J S Chapman; R Cleeland; L M Cummings; B A Dix; D D Keith
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

7.  Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.

Authors:  J G Christenson; K K Chan; R Cleeland; B Dix-Holzknecht; H H Farrish; I H Patel; A Specian
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

8.  In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; B Holzknecht
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  New beta-lactamase-resistant cephem treatment of guinea pigs infected with Legionella pneumophila.

Authors:  J Toro; K Sawatari; T Kanda; A Saito; K Hara
Journal:  Microbiol Immunol       Date:  1983       Impact factor: 1.955

10.  Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions.

Authors:  D M Liebers; A L Baltch; R P Smith; M C Hammer; J V Conroy
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790
View more
  5 in total

1.  In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; F Higa; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

2.  In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; T Shinzato; E Doyle; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  In vitro activity of RP 74501-RP 74502, a novel streptogramin antimicrobial mixture, against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

4.  In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Ren; R Polzer; R P Gladue
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.